Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with prazosin in a clinical setting.

R R Moyer

    Postgraduate Medicine
    |November 1, 1975
    PubMed
    Summary

    Prazosin is a safe antihypertensive medication for patients with gout, kidney disease, or borderline diabetes. It spares organ systems often damaged by other blood pressure drugs.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Remission of mild to moderate hypertension after treatment with carteolol, a beta-adrenoceptor blocker with intrinsic sympathomimetic activity.

    Archives of internal medicine·1988
    Same author

    A double-blind study of trimazosin and methyldopa in hypertensive patients receiving polythiazide.

    American heart journal·1983
    Same author

    Verapamil. An anti-anginal agent.

    Minnesota medicine·1972
    Same author

    Intrathoracic meningocele; a case report.

    The American journal of medicine·1957

    Area of Science:

    • Pharmacology
    • Nephrology
    • Endocrinology

    Background:

    • Hypertension management presents challenges in patients with comorbidities.
    • Traditional antihypertensive agents can negatively impact organ systems.
    • Identifying safer treatment options is crucial for patient outcomes.

    Purpose of the Study:

    • To evaluate the suitability of prazosin for hypertensive patients with specific comorbidities.
    • To assess the organ-sparing properties of prazosin compared to other antihypertensives.

    Main Methods:

    • A three-phase study initiated in 1969.
    • Clinical assessment of prazosin efficacy and safety.
    • Comparative analysis of organ system impact.

    Main Results:

    • Prazosin demonstrated particular suitability for hypertensive patients with gout.
    • Prazosin was effective in hypertensive patients with renal disease.
    • Prazosin showed benefits for hypertensive patients with borderline diabetes.
    • The drug spared organ systems frequently harmed by other antihypertensives.

    Conclusions:

    • Prazosin is a well-tolerated antihypertensive option for patients with gout, renal disease, or borderline diabetes.
    • Its organ-sparing profile makes it a valuable therapeutic choice.
    • Prazosin offers a safer alternative for managing hypertension in complex patient populations.

    Related Experiment Videos